
PFS Benefit of Ide-cel in Myeloma Maintained in Higher-Risk Population
Patients with relapsed multiple myeloma can receive a variety of options based on which agents they have received in prior lines of therapy, but now oncologists are looking toward the approved chimeric antigen receptor (CAR) T-cell therapies, particularly …